Cardiochirurgia E.H.
14
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
21.4%
3 terminated/withdrawn out of 14 trials
75.0%
-11.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
DOSE FINDING PROSPECTIVE ANALYSIS AFTER HEART SURGERY for Sucrosomial Iron
Role: lead
Multicenter Randomised Prospective Study for External Support Mesh VEST of Venous Coronary Grafts on the Right Territory
Role: lead
VEST Device to Enhance Safein Vein Patency
Role: lead
ITA Vs LAD; Evaluation of Inflammatory Burden in OP-CABG Patients
Role: lead
CO2 Field Saturating Alternative Techniques Comparison
Role: lead
Meshed Vein Graft Patency Trial - VEST
Role: lead
CardioSideral Heart Surgery: Randomized Study on Sucrosomial Iron Supplementation Before Heart Surgery
Role: lead
Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Redo Cardiac Surgery
Role: lead
Plasty or Prosthesis to Treat Functional Mitral Regurgitation
Role: lead
Platelets Antiaggregation Control Enhancement (PACE) Study
Role: lead
Prospective Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery
Role: lead
Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery
Role: lead
Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.
Role: lead
ICU Cell Saver to Reduce Blood Transfusions in Cardiac
Role: lead
All 14 trials loaded